Find a Clinical Trial

Showing 11 - 20 of 39 Trials

  • A Phase 1 Study of SGN-B6A in Advanced Solid Tumors

    Principal Investigator:

    Lanyi Nora Chen, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04389632

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to study SGN-B6A alone, with pembrolizumab, or with pembrolizumab and one of the chemotherapy drugs (cisplatin or carboplatin). The sponsor wants to find out what its side effects are and if it works for specific types of cancer. It is not yet know if SGN-B6A alone or with other drugs is better or worse than other treatments. This clinical trial uses an experimental drug. This means the Food and Drug Administration (FDA) hasn’t approved it for sale in the United States. This drug is called SGN-B6A. This clinical trial also uses pembrolizumab. The brand name...

  • RANDOMIZED TRIAL OF LIMB CRYOCOMPRESSION VERSUS CONTINUOUS COMPRESSION VERSUS LOW CYCLIC COMPRESSION FOR THE PREVENTION OF TAXANE-INDUCED PERIPHERAL NEUROPATHY

    Principal Investigator:

    Melissa Accordino, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05642611

    Population:

    Adult

    Phase:

    III
    The purpose of this study is to learn which of the following 3 study approaches is the most helpful to prevent peripheral neuropathy caused by taxane chemotherapy. These approaches will use a study device, called the Paxman Limb Cryocompression System, made of wraps that cool and/or compress your arms and legs. The study will test which of the following combinations of cooling and/or compression to your arms and legs is better at preventing peripheral neuropathy: • Cryocompression (cooling plus moderate and low pressure to your arms and legs) • Continuous compression (moderate,...

  • A Phase 1a/1b Study of the PI3Ka:RAS Breaker BBO-10203 in Subjects with Advanced SolidTumors (The BREAKER-101 Trial)

    Principal Investigator:

    Linda Y. Wu, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06625775

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to find the best dose and effects of BBO-10203 when used alone or in combination with Trastuzumab in HER2-positive advanced breast cancer (aBC) or HR- positive, HER2-negative aBC or advanced non-small cell lung cancer (aNSCLC) with a KRAS (Kirsten rat sarcoma) mutation or advanced colorectal cancer (aCRC) with a KRAS mutation.BBO-10203 has not been approved by the Food and Drug Administration (FDA). Trastuzumab is FDA approved but not in combination with BBO-10203. This is a first in human study. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older...

  • A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 asMonotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT07277413

    Phase:

    I
    The purpose of this study is to determine the ideal dose of the study drugs, IDE892 by itself and IDE892 in combination with IDE397, and to find out what effect, good and/or bad, these study drugs may have on your cancer. This will be first human study for IDE892. Both IDE892 and IDE397 has not been approved by the United States (US) Food and Drug Administration (FDA). Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Must be willing and able to provide blood/tumor tissue samples for biomarker testing - Must be able to swallow and retain the study drug

  • An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04794699

    Population:

    Adult

    Phase:

    I
    IDE397 is an investigational drug, which has not been approved by health authorities for the treatment of people with your medical condition. It is currently not “on the market” (available for you to receive a prescription for and/or to buy) in any country. In this study, different dose levels of IDE397 will be tested. About 40 patients are expected to participate at approximately 6-8 study centers within the US. At a minimum, 2 patients will be enrolled in each dose level. There will be about 10 dose levels tested (starting at 5 mg). Every time a dose level is found to be safe, a...

  • Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT)

    Principal Investigator:

    Eileen Patricia Connolly, MD, PhD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06745024

    Phase:

    III
    This study is being done to answer the following question: Will preventative radiation therapy lower the number of bone metastases-related complications (such as fracture caused by the tumor in the bone and tumor pushing on the spinal cord) compared to the usual approach? We are doing this study because we want to find out if this approach is better or worse than the usual approach for patients with high risk bone metastases. The usual approach for patients who are not in a study is drugs that prevent bone loss, in addition to continuing to receive drug treatment for their primary cancer, or...

  • A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB1305 inParticipants with Advanced/Metastatic Solid Tumors

    Principal Investigator:

    Brian Henick, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06953089

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test whether combining two investigational study drugs, DB-1311 with BNT327 or DB-1311 with DB-1305, is safe and can be tolerated by participants with advanced or metastatic solid tumors. The study will also test how much of the study drugs are in the blood at different times, if the body makes antibodies against the study drugs, and how the study drugs affect the disease. Additionally, the study may also explore how certain molecules in the blood or tissue (biomarkers) relate to the drug's effects. DB-1311, BNT327, and DB-1305 are investigational drugs,...

  • A Phase 1 Open-Label Study of PF-07985045 as a Single-Agent and in Combination with Other Anti-Cancer Agents in Participants with Advanced Solid Tumors

    Principal Investigator:

    Linda Y. Wu, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06704724

    Population:

    Adult

    Phase:

    I
    The purposes of this research study are (1) to learn about the safety and the effects of study drug, PF-07985045 on your specific cancer and on your body, with or without combination drugs and (2) to find the best dose for treating your specific type of cancer, as well as treating other types of cancers. This study is divided in two parts: Part 1 and Part 2. Part 1 testing and results applies to the study drug alone, called monotherapy. The goal of Part 1 is to determine the maximum tolerated dose (highest dose that is safe and tolerable in study participants, called MTDM and the recommended...

  • A Phase 1a/1b Study of the pan-KRAS Inhibitor LY4066434 in Participants with KRAS Mutant SolidTumors

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06607185

    Population:

    Adult

    Phase:

    I
    This research study is being done to test the safety of an investigational treatment called LY4066434 when given alone or with other cancer drugs. LY4066434 is an investigational (or experimental) drug, taken orally. It was designed for patients that have abnormalities (also known as DNA mutations) in the KRAS gene that can occur in some types of cancer. LY4066434 is not approved by the U.S. Food and Drug Administration. Are you Eligible? (Inclusion Criteria) Must be ≥18 years of age, 2. Must be able to swallow tablets. 3. Must be able to comply with outpatient treatment, laboratory...

  • A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors

    Principal Investigator:

    Linda Y. Wu, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT07023731

    Population:

    Adult

    Phase:

    I/II
    The purpose of this study is to test ARV-806 in people who have advanced cancer with KRAS G12D mutation. Advanced cancer is cancer that has spread or come back. KRAS G12D mutation is a change in the cancer DNA that may encourage cancer growth. ARV- 806 is experimental. This means that the Food and Drug Administration (FDA) has not approved the drug for sale or use for the treatment of advanced cancer with KRAS G12D mutation. This study is trying to find out the right dose of the drug that can be given without causing unacceptable side effects. Are you Eligible? (Inclusion Criteria) Written...

Pages

Back to top